Weekly highlights, Nov 9 – Nov 15, 2026
A psilocybin treatment reached the FDA application stage, while proposed US production quotas pointed to growing research demand. A mushroom discovery also raised a new poisoning concern.
-
1
Compass Pathways submits COMP360 psilocybin application to FDA for treatment-resistant depression
Compass submitted its psilocybin treatment for FDA review in treatment-resistant depression, drawing on data from over 1,000 participants.
-
2
Florida discovery identifies Galerina indica as the first known mushroom containing both psilocybin and poisonous amatoxins
Galerina indica is the first known mushroom to contain both psilocybin and poisonous amatoxins, posing an identification risk.
-
3
DEA proposes a 57-fold increase in the 2027 ibogaine production ceiling, but the quota does not establish supply
The DEA proposed a 57-fold increase in the ibogaine production ceiling for research, though a higher quota does not guarantee supply.
-
4
Hoch dosiertes LSD steigert Hirnaktivität bei einer Arbeitsgedächtnisaufgabe bei Menschen mit Depression
A study links high-dose LSD to increased brain activity during a working memory task in people with depression, independent of mood change.
-
5
Festival «Substanzen Jetzt.» verbindet psychedelische Forschung, Kunst und Gegenkultur in der Photobastei Zürich
A Zurich festival brings psychedelic research and therapy into conversation with art, counterculture and harm reduction.